Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Lipiodol + idarubicin for unresectable hepatocellular carcinoma in Child-Pugh A/B7 cirrhosis
2017-004859-22Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idarubicin in hepatocellular carcinoma (HCC), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Disease control rate at 4 months. Started Apr 2018; status: active.
02
Drugs
idarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2017-004859-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004859-22.